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Abstract
The functional consequences of genetic variation in mammalian regulatory elements are poorly 
understood. We report the in vivo dissection of three mammalian liver enhancers at single 
nucleotide resolution via a massively parallelized reporter assay. For each enhancer, we 
synthesized a library of >100,000 mutant haplotypes with 2–3% divergence from wild-type. Each 
haplotype was linked to a unique sequence tag embedded within a transcriptional cassette. We 
introduced each enhancer library into mouse liver and measured the relative activities of 
individual haplotypes en masse by sequencing of the transcribed tags. Linear regression yielded 
highly reproducible estimates of the impact of every possible single nucleotide change on 
enhancer activity. The functional impact of most mutations was modest, with ~22% impacting 
activity by >1.2-fold, and only ~3% by >2-fold. These results suggest that mammalian enhancers 
are relatively robust to single nucleotide changes. Several, but not all positions with higher impact 
showed evidence for purifying selection, or co-localized with known liver-associated transcription 
factor binding sites, demonstrating the value of empirical high-resolution functional analysis.
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INTRODUCTION
Massively parallel sequencing has accelerated the cataloguing of cis-regulatory elements in 
mammalian genomes1–3. However, we still lack a high-resolution understanding of the 
functional basis of activity for the overwhelming majority of cis-regulatory elements. 
Understanding the architecture and internal grammar of cis-regulatory elements is essential 
for advancing our comprehension of the mechanistic basis for regulatory activity, for 
enabling the de novo design of synthetic regulatory elements, and for predicting the 
functional and phenotypic consequences of genetic variation within non-coding DNA.
Although diverse methods exist to predict the functional consequences of protein-altering 
variants, we remain poorly equipped to estimate the functional impact of regulatory 
variants4. Recent studies have highlighted the importance of regulatory variants. For 
example, disease-associated variants frequently coincide with regulatory regions, and in 
particular with enhancers2, 5–8. As a step forward, we sought to assess the spectrum of effect 
sizes of all possible single nucleotide variants (SNVs) on the functional activity of three 
mammalian enhancers with demonstrated in vivo activity in the liver, designated here 
ALDOB (hg19:chr9:104195570-104195828)9–11, ECR11 
(hg19:chr2:169939082-169939701)12, 13, and LTV1 (mm9:chr7:29161443-29161744).
We previously reported a method called “synthetic saturation mutagenesis”14 in which 
programmable microarrays were used to synthesize variants of several regulatory elements 
(core promoters), each in cis with a downstream tag sequence. The population of core 
promoter variants was subjected to a cell-free in vitro assay, after which RNA-Seq of the 
tags was used to quantify the relative activity of specific core promoter variants. Although 
successful, several aspects of this approach limit its broader application and scalability: 1) 
When each regulatory element variant is synthesized as a separate array feature, the overall 
cost of synthesis remains high. 2) The separate synthesis of individual variants also limits 
how many combinations of mutations can be simultaneously programmed. 3) The maximum 
length of array-synthesized oligonucleotides is currently 200–300bp, whereas mammalian 
enhancers can be 1 kilobase or longer. 4) Access to array-derived oligonucleotide libraries 
remains restricted to a few groups. 5) The cell-free, in vitro assay that we used poorly 
captures biological context.
To circumvent these limitations and enable the high-resolution dissection of mammalian 
enhancers, we developed a new method (Figure 1). In brief, each enhancer of interest is 
synthetically constructed by polymerase cycling assembly using overlapping 
oligonucleotides (~90bp) containing a programmed level of degeneracy. At each position, 
97% of molecules are expected to be synthesized correctly with 1% doping of each possible 
single nucleotide substitution (Online Methods). Therefore, each synthetic enhancer 
molecule contains, on average, 3 mutations per 100bp, randomly distributed along its length. 
The population of molecules is inherently complex, both with respect to representation of all 
possible SNVs of the wild-type enhancer as well as myriad unique combinations. Because 
nearly all synthetic enhancers contain multiple substitutions, they are referred to here as 
“enhancer haplotypes”. The enhancer haplotypes are cloned into a plasmid (Promega 
pGL4.23), which contains a minimal promoter upstream of the luciferase gene. In order to 
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uniquely tag each enhancer haplotype, an oligonucleotide containing a 20bp fully degenerate 
subsequence is cloned to a separate site, in the 3′ UTR of the luciferase gene. The sequences 
of specific 20bp tags cloned in cis with specific enhancer haplotypes are determined by 
massively parallel sequencing. As the enhancer haplotypes are highly related sequences with 
lengths that exceed the maximum read-length of the Illumina platform, we use tag-guided 
subassembly15 to enable full-length, high-accuracy sequencing of individual enhancer 
haplotypes in association with their downstream tags. Each resulting library includes 
>100,000 fully sequenced enhancer haplotypes, with nearly all containing multiple 
substitutions and each associated with one or more unique tags. The library is then subjected 
to what is effectively a highly multiplexed reporter assay, either in vitro or in vivo. For the 
experiments described here, we used the hydrodynamic tail vein assay12, 16 to assess in vivo 
enhancer activity in the mouse liver. Mice were sacrificed 24 hours post-injection, at which 
time total RNA was extracted from each liver, followed by RT-PCR and massively parallel 
sequencing of cDNA from transcribed tags.
The enhancers studied here were identified by diverse methods (Supplementary Fig. 1). 
ALDOB (259bp) is a human intronic enhancer of the aldose B gene9–11. ECR11 (620bp) is a 
human enhancer located in an intron of dehydrogenase/reductase SDR family member 9 
(DHRS9)12. LTV1 (302bp) is a candidate mouse enhancer located 3′ of zinc finger protein 
36 (Zfp36) (Supplementary Fig. 2a,b). The functional activity of each wild-type enhancer 
was confirmed using a conventional hydrodynamic tail vein injection assay, in which 
luciferase activity in liver tissue was measured 24 hours post-injection (Supplementary Fig. 
2c).
RESULTS
Synthetic saturation mutagenesis and massively parallel readout
To systematically dissect the functional consequences of all possible SNVs in these three 
enhancers, we applied to each the workflow described above (Figure 1). Sequencing with 
subassembly confirmed that the resulting libraries were complex, with a total of 641,135 
distinct haplotypes associated with 1,186,696 tag sequences (Table 1). The observed number 
of mutations per haplotype approximated expectations, with ~2–3 substitutions per 100bp 
(Supplementary Fig. 3) and were well-distributed (Supplementary Fig. 4). All possible 
substitution variants of each enhancer were represented in ≥42 uniquely tagged haplotypes, 
with each position disrupted on an average of ~4,000 distinct enhancer haplotypes. 
Furthermore, all possible pairs of positions were disrupted in ≥1 haplotype with the 
exception of a single pair of positions in LTV1.
We introduced each library (one each for ALDOB and ECR11, and two independently 
constructed libraries for LTV1) into two mice via hydrodynamic tail vein injection 
(Supplementary Fig. 2d). Total RNA from each mouse was split into several pools, with 
each aliquot separately subjected to RT-PCR with primers flanking the 20bp tag located in 
the 3′ UTR of the luciferase transcriptional cassette, and then to massively parallel 
sequencing on an Illumina GA2x. Because target RNA was very scarce relative to cellular 
RNA, a modest number of target RNA molecules contributed to each RT-PCR, leading to a 
complexity bottleneck. In other words, within each sequencing library, all reads 
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corresponding to any single tag appeared to have been derived from amplification of a single 
RNA molecule. We therefore used the number of RNA pools in which a particular tag was 
observed, and not the total number of reads associated with a tag, as a measure of the 
relative transcriptional activity of its associated enhancer haplotype.
For each position in each enhancer, we constructed a linear model to assess the extent to 
which the presence of a mutation at that position is predictive of a change in the number of 
RNA pools in which an enhancer haplotype was observed, which is effectively a proxy for 
its impact on transcriptional activation, i.e. “effect size” (Online Methods). Specifically, we 
use the term “effect size” to describe the log2 fold change in the predicted transcriptional 
activity, as measured by the number of RNA pools in which a tag-associated haplotype 
appeared, relative to the wild-type. We first sought to assess reproducibility, so we 
calculated effect sizes separately for the two independently constructed LTV1 libraries 
(pooling data from the two mice subjected to each of these libraries). For ALDOB and 
ECR11, we calculated effect sizes separately on the data from each mouse. For these two 
types of biological replicates, the effect sizes were highly correlated (r=0.96 for LTV1, 
r=0.93 for ALDOB, r=0.96 for ECR11). Based on this high reproducibility and to increase 
resolving power, we performed all subsequent analyses after combining data across mice for 
each enhancer haplotype library (data for one of the two LTV1 replicate libraries is shown in 
Supplementary Fig. 5).
We next recalculated effect sizes in two ways (Online Methods). First, as for the 
reproducibility analysis, we constructed separate linear models for each position where 
mutational status was encoded as a single binary variable representing whether an enhancer 
haplotype was wild-type or mutant at that position (Fig. 2a,c,e, Supplementary Table 1a). 
Second, we constructed separate multiple linear regression models for each position with 
three variables, each corresponding to a particular nucleotide substitution at that position 
(Fig. 2b,d,f, Supplementary Table 1b). For each enhancer, we also constructed a multiple 
linear regression model incorporating all positions. These models were also significantly 
predictive (Supplementary Note 1; Supplementary Table 2), and yielded effect size profiles 
similar to models constructed independently for each position (Supplementary Fig. 6). As 
the coefficients from models constructed independently for each position are more naturally 
interpreted as position-specific effects, we used these models for subsequent analyses.
To provide further validation, we also performed site-directed mutagenesis to individually 
introduce the six mutations in ALDOB that were predicted to have amongst the largest 
effect sizes (three increasing activity, and three decreasing activity), and tested these 
individually via the hydrodynamic tail vein luciferase assay (Supplementary Fig. 7). 
Observed luciferase fold-changes were highly correlated with effect size predictions from 
the models (R=0.985).
Spatial clustering of high impact sites and concordance with known TFBSs
Across each enhancer, the effect size profiles exhibited spatial structure - i.e., a clustering of 
positions with larger effect sizes. Positions separated by less than ~6 nucleotides had 
significantly correlated effect sizes (Supplementary Fig. 8). To further explore this, we 
performed multiple linear regression using mutational status at 10 adjacent positions (i.e., a 
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binary variable for wild-type or mutant) at a time (Online Methods). These models remained 
significantly predictive of transcriptional activity in a spatially resolved pattern (Fig. 2a,c,e). 
We suspected that these clusters of correlated positions might represent TFBSs. Indeed, 
when we predict TFBSs17 (Fig. 2a,c,e; Supplementary Table 3), we observe striking overlap 
between predicted binding sites and clusters of highly predictive positions (Fig. 2a,c,e). For 
example, a predicted binding site for HNF4 in the ALDOB enhancer (bases 94–105) 
coincides with a highly predictive localized model (Fig. 2a). Furthermore, all mutations in 
this region had negative effects on activity, with the notable exception of mutations that 
increased identity with the consensus HNF4 binding site, which were activating (e.g., 
95A→G and 105T→A) (Fig. 3a). The same pattern was observed for other predicted sites as 
well, e.g. a predicted HNF1 binding site at bases 135–148 in ALDOB (Fig. 3b). Notably, 
independent experiments have established that these two transcription factors drive this 
element in vivo11. The spatial patterns may also reveal or refine broader features of activity 
– e.g. the boundaries of functional elements. For example, in ECR11, computational 
prediction yielded a large number of predicted liver-specific TFBSs in the proximal 300 
bases12, but we observed that the highest impact SNVs were largely confined to the distal 
160 bases (Fig. 2d; Supplementary Fig. 9).
Relationship between evolutionary conservation and functional constraint
Evolutionary constraint in non-coding, regulatory DNA has frequently served as a proxy for 
functional constraint18–20. However, recent studies have shown that many enhancers are 
evolving rapidly and that mammalian genomes contain large numbers of evolutionarily 
young, sometimes species-specific, enhancers21, 22. All three enhancers studied here are 
grossly conserved between human and mouse (Supplementary Fig. 1). We therefore 
investigated the relationship between functional constraint and evolutionary constraint at 
single nucleotide resolution. For two of three enhancers, linear models, constructed to assess 
whether evolutionary constraint (i.e. Genomic Evolutionary Rate Profiling (GERP)23) was 
predictive of functional constraint (i.e. the absolute value of univariate model coefficients 
that we obtained), were significantly predictive with modest explanatory power (ALDOB: 
R2=0.1232, p=6.31e-9; LTV1: R2=0.03911, p=5.47e-4). For both enhancers, positions with 
the highest functional effect sizes were significantly associated with elevated evolutionary 
constraint scores (Supplementary Fig. 10). However, not all positions with high GERP 
scores (≥4) had functional effect sizes in the top quartile for each enhancer (ALDOB: 33 of 
61, 54%; ECR11: 5 of 25, 20%; LTV1: 0 positions with GERP≥4). These sites might have 
functions unrelated to the enhancer activity assayed here or might be of greater functional 
relevance in other contexts, e.g. other tissues or developmental time points. On the other 
hand, a small set of highly functional sites, e.g. most nucleotides within the distal-most 
C/EBP motif in ECR11, have low GERP scores, consistent with lineage or species-specific 
activity.
Effect size spectrum of of single nucleotide variants
A substantial proportion of polymorphisms and new mutations in mammalian genomes are 
single nucleotide substitutions24. However, the functional dissection of regulatory elements 
has historically relied on introducing nested or scanning deletions, limiting the extent to 
which they inform the interpretation of naturally occurring variation. Our results provided an 
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opportunity to examine the distribution of effect sizes of SNVs in mammalian enhancers on 
the magnitude of transcriptional activation (Fig. 4). Surprisingly, we observed that the 
majority of SNVs result in only a modest change in transcription relative to the wild-type 
enhancer. Overall, fewer than 25% of the mutations alter transcriptional activity by >1.2-
fold. Furthermore, only a few mutations, mostly in ALDOB, altered activity by a factor of 
>2-fold. These results suggest that these enhancers are highly robust to the vast majority of 
potential SNVs. Further application of this method will be needed to assess whether this is a 
general property of mammalian enhancers.
Perhaps as expected, the majority of functionally significant mutations decreased activity 
(70% or 850/1211). In general, only one substitution at a given position was activating, e.g. 
substitutions that render a motif more consensus-like (Fig. 3). However, we observed some 
notable exceptions, including positions 83–93 and 272–278 in LTV1, where all or almost all 
substitutions are activating, consistent with binding of a repressive transcription factor. 
Positions 83–93 harbor a predicted binding site for NF-1, while there are no predicted sites 
in the immediate vicinity of positions 272–278, highlighting the value of experimental 
assessment of mutational impact.
Epistatic interactions
Finally, we sought to leverage the fact that our enhancer libraries contain multiple mutations 
on each haplotype to assess the degree of epistasis or interaction. To obtain adequate power, 
we restricted our analysis to pairs of positions that were both mutated in at least 20 
haplotypes. For each pair of positions that passed this cutoff, we built a multiple linear 
regression model consisting of three binary variables where the first two variables encoded 
mutation status (wild-type or mutant) at each position independently and the third encoded 
whether both are mutant in a particular haplotype (Online Methods). With an FDR cutoff of 
0.05, we observed few pairs with a significant interaction term (ALDOB: 82 of 33,389, 
0.25%; ECR11: 199 of 184,206, 0.10%, LTV1: 45 of 43,975, 0.10%), suggesting that the 
effects of multiple SNVs on the same haplotype are generally additive, or that our study 
lacked power to identify subtle interactions. Interacting pairs were significantly enriched for 
proximity (i.e. pairs within 10bp versus pairs further apart) and we observed several 
different classes of interacting pairs with respect to the signs of the individual position 
effects and the sign of the interacting term (Supplementary Table 4).
DISCUSSION
In summary, we developed a strategy to construct complex libraries of mammalian 
enhancers that contain all possible single nucleotide substitutions, and hundreds of 
thousands of distinct haplotypes. This method surpasses its predecessor14 in terms of cost-
effectiveness, tunability, applicability to full-length regulatory elements, and integration 
with an in vivo assay. We applied this method to empirically measure the distribution of 
effect sizes of all possible SNVs in three mammalian enhancers in an in vivo model. A key 
finding is that the vast majority of SNVs in these enhancers have highly reproducible yet 
remarkably modest effects on transcriptional activation. The distribution suggests that 
enhancers are highly robust to single nucleotide changes. We also find that the 
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preponderance of combinations of single nucleotide changes have additive effects on 
function. As expected, there is a clear relationship between the magnitude of functional 
impact and the location of predicted TFBSs, although not all predicted TFBSs are 
functional, and not all functional motifs are associated with predicted TFBSs. Similarly, 
evolutionary constraint, although clearly correlated with the magnitude of functional impact, 
does not predict it well on a nucleotide-by-nucleotide basis.
There remain some limitations of method performance. First, while we exploited a mouse 
tail vein assay to assess function in vivo, the regulatory elements are episomal and therefore 
may not be subject to the same mechanisms governing elements residing on chromosomes. 
For example, because of the size of the synthetic construct, we are unable to assess the 
impact of mutations that may influence long-range interactions between regulatory elements. 
This might be addressed in part by transitioning to a lentiviral system, which would facilitate 
use in additional tissues and may also enable the application of other assays, e.g. ChIP-Seq, 
to enhancer variant libraries. Furthermore, our results must also be considered specific to the 
minimal promoter used here until other promoter classes are tested. Second, we have only 
assayed these enhancers in a single tissue and at a single time point. The activity profile of 
specific positions could well be different in other tissues, i.e. the long-standing context 
problem25. Third, because of the scarcity of the target transcript relative to total RNA, we 
observed complexity bottlenecking, limiting the precision of our effect size estimates. This 
can be addressed by optimization of RNA isolation, e.g. by hybridization-based enrichment. 
Fourth, we restricted our analysis to enhancer haplotypes containing only substitutions, as 
this was the dominant form of variation introduced during synthesis. To facilitate 
simultaneous dissection of the functional consequences of small insertions and deletions 
(indels), one could use reduced-fidelity oligonucleotide synthesis conditions, or polymerase 
cycling assembly with oligonucleotides containing scanning block indels. Current efforts are 
directed at implementing these improvements, scaling this method to more enhancers, and 
applying it to other classes of non-coding regulatory elements.
A fundamental goal of modern biology is to understand the human genome at single 
nucleotide resolution. Single nucleotide differences between genomes are causative for, or 
impact susceptibility to, a host of diseases, and single nucleotide mutations are a primary 
source of raw material for evolution. We anticipate that the high-throughput, empirical 
measurement of the functional impact of single nucleotide variants in enhancers will 
substantially facilitate the analysis of non-coding variants in GWAS hits, the study of the 
mechanistic basis for enhancer activity, and the engineering of enhancers with desired 
properties. Furthermore, with cost-effective, massively parallel methods for functional 
analysis, it may soon be realistic to empirically measure the functional impact of all possible 
single nucleotide changes in all non-coding regulatory elements in the human genome.
ONLINE METHODS
Construction of enhancer haplotypes from short doped oligonucleotides using PCA
Sets of overlapping oligonucleotides for each enhancer were designed either by manual 
inspection (LTV1) or using the program DNAWorks (ALDOB and ECR11). Common 
flanking sequences were included on either side to allow for amplification of the full length 
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enhancer haplotypes during PCA. For LTV1, two versions of overlapping oligonucleotides 
were designed, such that the overlap region in each was different. Oligonucleotides were 
synthesized by Integrated DNA Technologies (IDT). All positions corresponding to the 
enhancer region were synthesized using a hand-mix doped at a ratio of 97:1:1:1 (i.e. 
designated base at a frequency of 97%, and every other base at a frequency of 1%). 
Sequences of all oligonucleotides are listed in Supplementary Methods.
For ALDOB as well as ECR11, the full length haplotypes were assembled in a single step. 
50fmol of each oligonucleotide (ALDOB_PCA_OLIGO[1…6] or 
ECR11_PCA_OLIGO[1…12]) were used in a 25μl PCR reaction volume with 1X KapaHiFi 
Hot Start Ready Mix (Kapa BioSystems), and 0.5X SYBR Green II, with the following 
cycling conditions: 95°C for 3min; followed by 30 cycles of 98°C for 20s, 65°C for 15s, 
72°C for 15s. Each sample was monitored and extracted from the PCR machine when 
fluorescence began to plateau. Four such reactions were carried out in parallel and then 
pooled together for each enhancer. The PCR product representing a complex pool of 
enhancer haplotypes was purified using QIAquick columns (Qiagen). The assembled 
enhancer haplotypes were then subjected to an additional around of PCR to add 15bp of 
vector homology on either side to render them competent for cloning using InFusion 
(Clontech). 20ng of template was used in a 25μl PCR reaction volume with 1X KapaHiFi 
Hot Start Ready Mix, 0.5x SYBR Green II, and each primer (VH_F and VH_R) at 0.3μM 
final concentration. Thermal cycling was performed with the following program: 95°C for 
3min; followed by 30 cycles of 98°C for 20s, 65°C for 15s, 72°C for 15s. Each sample was 
monitored and extracted from the PCR machine when fluorescence began to plateau. Sixteen 
such reactions were carried out in parallel and then pooled together for each enhancer. The 
PCR product was purified using QIAquick columns (Qiagen).
The two LTV1 designs were assembled separately. For each design, pairs of 
oligonucleotides i.e. oligonucleotides 1 and 2, oligonucleotides 3 and 4, and 
oligonucleotides 5 and 6 were each assembled in parallel and the products of the three 
reactions were then assembled together into the final product in a single reaction The 
combinations of primers and oligonucleotides used in each reaction are listed in 
Supplemetary Methods. Each 50μl PCR reaction was prepared on ice with 1X iProof Ready 
Mix (Bio-Rad), 0.5x SYBR Green II, forward and reverse primers each at 0.5μM final 
concentration, and 50fmol of each template oligo. Thermal cycling was done in a 
MiniOpticon Real-time PCR system (Bio-Rad) with the following program: 98°C for 30s, 
followed by 30 cycles of 98°C for 10s, 62°C for 30s and 72°C for 15s. Each sample was 
monitored and extracted from the PCR machine when fluorescence began to plateau. PCR 
products were purified on a QIAquick column (Qiagen). The haplotypes obtained from each 
of the two LTV1 designs were pooled after the PCA step. Two aliquots were drawn from 
this pool, and then carried through subsequent steps as two independent samples and were 
associated with entirely different sets of tags.
Cloning of enhancer haplotypes and the degenerate tag into pGL4.23
For ALDOB and ECR11, we first cloned in the degenerate tag to create a complex library of 
tagged pGL4.23 plasmids. We then cloned in the enhancer haplotypes into these tagged 
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pGL4.23 plasmids. For LTV1, we first cloned in the enhancer haplotypes and then cloned in 
the degenerate tag. Details of each cloning step remained the same, irrespective of the order 
in which they were carried out, and are described below.
Cloning of degenerate tag into pGL4.23 plasmid
The tag oligonucleotide (TAG_OLIGO) was made double-stranded using primer extension 
in a 50μl reaction volume with 1X iProof Master Mix, 0.5μg single stranded tag oligo, 0.5μg 
reverse primer (TAG_EXTEND). The reaction was incubated at 95°C for 3min, 61°C for 
10min, and then 72°C for 5min. The product was purified using a QIAquick column 
(Qiagen) and eluted in 50μL EB. It was further subjected to ExoI treatment in 40μL reaction 
volume for 1h at 37°C to degrade any remaining single stranded DNA, and purified again 
using Qia-Quick columns. The resulting double stranded tag oligo was then cloned into 
pGL4.23 at the XbaI site (at 1799bp) using standard InFusion (Clontech) protocol. The 
InFusion reaction was diluted to 100μl using TE8. 1.5μl of this diluted cloning reaction was 
used to transform 50μl of chemically competent FusionBlue cells (Clontech) using the 
standard protocol. When the tag was being cloned in first, sixteen such transformation 
reactions were pooled and grown overnight in four 50ml liquid cultures at 37°C in a shaking 
incubator. DNA was extracted using the Invitrogen Charge Switch Mini Prep Kit for 
ALDOB and ECR11, and the Invitrogen Charge Switch Midi Prep Kit for LTV1.
Cloning enhancer haplotypes into pGL4.23 vector
The enhancer haplotypes were cloned into the EcoRV site (at 42bp) of the pGL4.23 plasmid, 
using standard InFusion protocol. 1.5μl of the cloning reaction was used to transform 50μl of 
chemically competent FusionBlue cells (Clontech) using standard protocol. Five 
transformations reactions were pooled and grown overnight in 50ml liquid cultures at 37°C 
in a shaking incubator. DNA was extracted using the Invitrogen Charge Switch Mini Prep 
Kit for ALDOB and ECR11, and the Invitrogen Charge Switch Midi Prep Kit for LTV1.
Tail vein injections
Enhancers were injected using methods as previously described12. Briefly, each library was 
injected in at least 3 mice using the TransIT EE Hydrodynamic Gene Delivery System 
(Mirus Bio) following the manufacturer’s protocol. 10ug of each library, alongside 2μg of 
pGL4.74[hRluc/TK] vector to correct for injection efficiency, was injected into the tail vein 
of CD1 mice (Charles River). Following 24h, mice were euthanized and livers were 
harvested.
Measurement of luciferase activity
Firefly and renilla luciferase activity were measured on a Synergy 2 Microplate Reader 
(BioTek Instruments, Inc.) for each liver using the Dual Luciferase Reporter Assay System 
(Promega). The firefly luciferase to renilla luciferase ratios were determined and expressed 
as relative luciferase activity. All mouse work was approved by the UCSF Institutional 
Animal Care and Use Committee.
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Isolation of RNA from mouse livers
Fresh liver tissue was immediately stabilized in RNAlater solution (Ambion). Samples were 
homogenized in TRIzol reagent (Invitrogen) and RNA was isolated from the samples 
according to the manufacturer’s instructions.
DNase treatment of RNA
In order to remove any DNA contamination in the RNA extracted from mouse livers, it was 
subjected to DNaseI treatment using DNA-free (Ambion). Each reaction was prepared with 
1x DNA-free Buffer, 1μl of rDNaseI enzyme, 10μg of RNA and RNase-free water to 50μL. 
The reactions were incubated at 37°C for 1h, with an additional 1μl of enzyme added mid-
way through the incubation. The reaction was stopped by adding 7μl of the Inactivation 
reagent and incubating for 2min at room temperature with frequent shaking. The reaction 
was centrifuged in a microcentrifuge at >13,000rpm for 1.5min, and the supernatant 
containing RNA was carefully transferred to a fresh tube.
RT-PCR
Aliquots of RNA obtained after DNase treatment were reverse transcribed to cDNA and 
amplified by PCR using the Qiagen One-Step Kit. The PCR sought to amplify the 20bp 
degenerate tag encoded at the 3′ end of the luciferase transcript. The reactions were 
assembled on ice in a 25μL total volume with the following reagents: 1X Qiagen One-Step 
RT-PCR buffer, 400μM of each dNTP, 0.6μM of forward primer (BARCODE_PE_F), 
0.6μM of relevant reverse primer (BARCODE_PE_R_ILMN_INDEX[1-8]), 0.5x SYBR 
Green II and 5μl (~1μg) of RNA template. Thermal cycling was performed on a Bio-Rad 
MiniOpticon Real-Time PCR system with the following program: 50°C for 30min (reverse 
transcription), 95°C for 15min (inactivation of reverse transcriptase and heat-activation of 
the DNA polymerase), then 30 cycles of 94°C for 30s, 65°C for 30s and 72°C for 30s. Each 
reaction was monitored and extracted from the PCR machine when the fluorescence began 
to plateau. The cDNA products were purified using the QIAquick PCR Purification Kit 
(Qiagen) and eluted in 35μl EB. The primers used for the RT-PCR contained the necessary 
sequences for compatibility with the Illumina flow-cell. Thus, the cDNA library obtained at 
the end of this step was sequencing-ready, eliminating the need for a separate sequencing 
library construction step. The reverse primer additionally included 6bp barcodes allowing 
for several RT-PCR reactions to be pooled into a single lane for sequencing.
Sequencing of tags
The pooled RT-PCR reaction products were sequenced on an Illumina GAIIx using a 
sequencing primer (BARCODE_SEQ_F) designed to read into the tag sequence. Each run 
was 36 cycles with an additional 6 cycles to read the indexing barcode (index sequencing 
primer: GTCTCCCCGTTTAATCCCATCTAGAGTCGA ).
For each pool, reads were filtered based on the quality scores for the first 20 bases which 
correspond to the degenerate tag. The numbers of occurrences of each tag were counted and 
tags that were supported by at least 10 reads were classified as being “present” in that pool.
Patwardhan et al. Page 10
Nat Biotechnol. Author manuscript; available in PMC 2012 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Associating tags with enhancer haplotypes
The enhancer haplotypes and tags were situated more than 1000bp away from each other on 
the pGL4.23 plasmid. To bring them adjacent and facilitate the subassembly method, we 
digested the pGL4.23 plasmids using HindIII, which had two cut sites, one just 3′ of the 
enhancer, and one just 5′ of the tag, thus resulting in excision of the intervening region. Cut 
site 1 was already a part of the pGL4.23 backbone. Cut site 2 was engineered in as a part of 
the tag oligo. The digest was carried out in a 50μl volume with 1X NEB Buffer 2, 1μg of 
plasmid and 1μl of HindIII Enzyme (New England BioLabs) and incubated at 37°C for 3h. 
The digested plasmid was purified using a QIAquick column (Qiagen).
The digested plasmids were then re-circularized using intra-molecular ligation, resulting in 
the tag becoming adjacent to the 3′ end of the enhancer. Ligation was performed using T4 
DNA ligase (New England BioLabs) in a 20μl reaction with 15ng of template per reaction. 
The reaction was incubated for 15min at room temperature, followed 20min at 65°C to 
inactivate the ligase.
The enhancer and tag region were amplified from re-circularized plasmids using PCR with 
the forward primer targeting the region immediately 5′ of the enhancer (ENHANCER_F for 
ALDOB and ECR11, and LTV1_F for LTV1) and the reverse primer targeting the region 
immediately 3′ of the tag (BARCODE_PE_R). The reaction was carried out in a 25μl 
volume with 1X KapaHiFi Hot Start Ready Mix (Kapa BioSystems), 0.5x SYBR Green II, 
5μl of the ligation reaction, and each primer at 0.3μM final concentration. Thermal cycling 
was carried out using Bio-Rad MiniOpticon Real-Time PCR system using the following 
program: 95°C for 3min; and then 30 cycles of 98°C for 20s, 65°C for 15s, 72°C for 15s. 
Each reaction was monitored and removed from the PCR machine when the fluorescence 
began to plateau. The reactions were then pooled and purified using QIAquick columns 
(Qiagen).
The amplicons were then subjected to the subassembly protocol as conceptually described in 
Hiatt et al15 with some modifications as follows. The random fragmentation step was carried 
out using the Nextera Tn5 transposase (EpiCentre) instead of mechanical shearing. The 
Nextera reaction was purified using MinElute column (Qiagen) and size-selected by PAGE 
(LTV1: 100+; ECR11:100-300,300+; ALDOB: no size-selection performed). The size-
selected fragments were subjected to PCR in a 25μl reaction volume with 1X KapaHiFi Hot 
Start Ready Mix (Kapa BioSystems), 0.5x SYBR Green II, 5μl of the ligation reaction, 
Nextera Adapter 1 at 10nM final concentration, and primers Nextera BP1 and 
BARCODE_PE_R at 0.3μM final concentration each. Thermal cycling was carried out using 
BioRad Mini Opticon System using the following program: 95°C for 3min; and then 30 
cycles of 98°C for 20s, 65°C for 15s, 72°C for 15s. Each reaction was monitored and 
removed from the PCR machine when the fluorescence began to plateau. The PCR products 
were purified using a QIAquick column and then sequenced on either an Illumina GAIIx or 
a Hi-Seq 2000. Read1 collected 76bp/101bp of the enhancer sequence staring at random 
breakpoints along the enhancer. Read 2 collected the 20bp tag sequence.
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The reads were then grouped by tag. Reads belonging to each group were then aligned to the 
wild type enhancer sequence to identify the mutations on the haplotype associated with that 
tag using a custom analysis framework.
Estimation of effect size of mutation at each position along the enhancer (univariate 
model)
All linear regression analyses were performed using the lm() or lsfit() functions available in 
the R Statistical Package. To quantity the effect of mutation at any given position on the 
number of pools in which an enhancer haplotype was observed, we built a separate linear 
regression model at every position along the enhancer, with a single predictor representing 
whether the given position was wild-type or mutant. The predictor was thus a binary 
variable representing presence (1) or absence (0) of a mutation at that position.
where,
yi = number of pools in which the ith haplotype was observed (referred to as pool 
counts), and
Xij = 1 if position j was mutant and 0 if position j was wild-type in the ith haplotype.
To facilitate comparison between positions and between enhancers, we calculated the “effect 
size” of mutation at a position j as:
The p-value reported by the model for β1j was used to judge whether the effect size was 
significant.
For LTV1, since a single haplotype was typically associated with multiple tags, we 
normalized the pool counts for a given haplotype by dividing by the number of tags 
associated with that haplotype. In case of ALDOB and ECR11, since the enhancer 
haplotypes were cloned in second, almost all haplotypes were associated with single tags, 
and thus the pool counts for tags were used directly as the pool counts of their linked 
haplotypes.
Estimation of effect size of each specific nucleotide change at each position along the 
enhancer (trivariate model)
To explore whether the estimated effect sizes for each position were being driven by specific 
nucleotide substitutions, we modified the model just described to include three predictors, 
each representing one of the three possible nucleotide substitutions at that position. The 
factors were set up as binary variables representing the presence (1) or absence (0) of the 
particular change at that position.
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Effect sizes were then calculated from the coefficients produced by the models as follows 
(for k=1,2,3):
The p-value reported by the model for βkj was used to judge whether the effect of a given 
nucleotide substitution at a given position was significant.
Spatial Structure
To quantify whether nearby sites tend to have similar effect sizes, we calculated the sum of 
the absolute values of the differences in effect sizes between positions located at a given 
distance (lag) from each other. In other words, we calculated , 
where k=1,2,…,20 denotes the lag, N denotes the length of the enhancer, and ri is the effect 
size of position i.
For each value of the lag k, we also calculated S1,*(k), …,S1000,*(k), each of which measures 
the sum of the absolute values of the differences in effect sizes between positions at a 
distance k from each other, after permuting the effect sizes (r1, …,rN). We then calculated a 
p-value associated with each value of the lag k as the fraction of the S1,*(k), …,S1000,*(k) 
that was as small or smaller than S(k).
Models to estimate combined predictive power of blocks of adjacent positions
To further characterize the nature of the spatial structure of the effect sizes and to explore 
whether certain regions along the enhancer were enriched for sites with larger effect sizes, 
we focused on blocks of adjacent sites in a 10bp sliding window along the length of the 
enhancer. For each window, we built a multiple linear regression model with one predictor 
for each position within the window. Each predictor was set up as a binary variable denoting 
the presence (1) or absence (0) of mutation at that site. The response variable y was the 
number of pools in which a given haplotype was seen.
The F-statistic from each model was used as a measure of the collective predictive power of 
positions within each window.
Multiple linear regression models based on the entire haplotype
The multiple linear regression model included one predictor for each position along the 
enhancer, encoded as a 1 or 0 to indicate presence or absence of a mutation at that site on a 
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given haplotype, and the response variable y represented the number of pools in which the 
haplotype was observed. Here N is the number of sites within a given enhancer.
A p-value for the model was calculated by comparing the mean squared error (MSE) of the 
model to MSEs of 200 models built using randomly shuffled versions of the response 
variable. A p-value for the model was estimated by calculating the fraction of times that the 
MSE for models built using a shuffled response vector was at least as small as the MSE 
computed using real data.
We then expanded the model, such that each position was represented by three predictors to 
indicate which of the three possible nucleotide substitutions was observed at that position.
A p-value for the model was calculated by repeatedly permuting the outcome vector as 
described earlier in the context of the univariate regression model; however, only 100 
permutations were used, due to the high computational burden of constructing this model.
Identification of epistatic interactions (i.e. non-additive effects) among pairs of mutations
For each pair of positions, we built a linear multiple regression model with three predictors: 
one predictor each to indicate the presence (1) or absence (0) of a mutation at each of the 
two positions and a third (referred to as the “interaction term”) whose value was set to 1 if 
both positions were mutant on the given haplotype and 0 otherwise. Only pairs of positions 
that were both mutant on at least twenty haplotypes were considered.
We used the p-values for the interaction terms for the resulting models to calculate a FDR 
for each interaction term (using the p.adjust() function in R, with method=”BH”). Interaction 
terms with FDR < 0.05 were considered significant and used for downstream analyses of 
epistatic interactions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Schematic illustration of the method
We used doped oligonucleotide synthesis and polymerase cycling assembly (PCA) to 
generate a highly complex library of enhancer haplotypes for each enhancer studied. On 
average, each enhancer haplotype diverged from wild-type by ~2–3% (red circles represent 
mutations). These mutant enhancers, along with 20bp random tags, were cloned into an 
expression vector (pGL4.23) containing a minimal promoter driving transcription of 
luciferase (minP/Luc). We performed “subassembly” on each library to determine the full 
sequence of each enhancer haplotype and to identify the 20bp tag to which each haplotype 
was cloned in cis. Each library was then introduced into two mice via hydrodynamic tail 
vein injection, livers were harvested after 24 hours, and RNA-seq was performed to quantify 
abundance of transcribed 20bp tags. These data were used to estimate the impact of each 
possible mutation on transcriptional activation.
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Figure 2. Effect size on transcriptional activity of all possible substitution mutations in three 
mammalian enhancers
Estimated effect size of mutation at each position based on coefficients from univariate 
(grey columns, left axis) and trivariate (A:red, C:blue, G:green, T:purple) models are shown 
for ALDOB ((a) and (b) respectively), ECR11 ((c) and (d) respectively), and LTV1 ((e) and 
(f) respectively). Effect sizes were estimated by taking the log2 of the ratio of the number of 
pools predicted by the model with a mutation to the number of pools predicted for the wild-
type nucleotide (total number of pools sequenced per library: ALDOB: 39; ECR11: 69; 
LTV1 Set 1: 10; LTV1 Set 2: 10). Effect sizes are only shown for positions where model 
coefficients had associated p-values ≤ 0.01. We also used multiple linear regression with 
sets of 10 adjacent positions as predictors. The F-statistic of these models, representing the 
extent to which the model is predictive of the outcome, is plotted (blue shadow, right axis) 
for ALDOB (a), ECR11 (c), and LTV1 (e). The locations of TFBS predictions using the 
MATCH web server (with restriction to TFs present in liver) are shown as horizontal grey 
bars at the top of the plot in (a), (c), and (e). The location of a partial LINE element in 
ECR11 is shown as an orange bar at the bottom of (c).
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Figure 3. Mutation effect size profiles in transcription factor binding sites
For a predicted HNF4 site (positions 94–105) (a) and a predicted HNF1 site (positions 135–
148) (b) in ALDOB, plotted is the effect size for each possible substitution, with the 
consensus TF binding sequence (orange) and the enhancer sequence (grey for consensus, 
black for non-consensus). Non-consensus positions where rescue is observed after mutating 
to consensus are shown in boldface. HNF4 binding to the ALDOB enhancer region in 
human liver has been previously demonstrated22, whereas in vivo occupancy data for HNF1 
at this region is not yet available.
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Figure 4. Distribution of effect sizes for all possible substitution mutations in three mammalian 
enhancers
For the three enhancers studied (two replicate libraries for LTV1), plotted is the cumulative 
fraction of substitutions possessing a given effect size expressed as the absolute value of the 
effect size of a given substitution. For example, across the three enhancers, between ~80% 
and ~95% of substitutions influence transcriptional activity by less than a factor of 1.5.
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